You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

32 Results
Guidelines and Advice
Status: Current
ID: PET 17
Jan 2017
Guidelines and Advice
Status: Current
ID: PET 18
May 2017
Drug
Other Name(s): Keytruda®
Updated
Sep 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Oct 2017
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and No Prior Ipilimumab
New Drug Funding Program
    Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and Prior Ipilimumab
Updated
Sep 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer (Second or Subsequent Line)
New Drug Funding Program
    Pembrolizumab - Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Updated
Sep 2025
Guidelines and Advice
Nov 2017
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Updated
Sep 2025

Pages